|Day's Range||34.98 - 35.60|
|52 Week Range||25.55 - 35.60|
|PE Ratio (TTM)||26.49|
|Dividend & Yield||1.90 (5.47%)|
|1y Target Est||34.12|
Tesaro's Zejula would likely outperform drugs from Clovis and AstraZeneca in immuno-oncology combinations with Merck, Bristol or Roche.
Regeneron (REGN) and Sanofi (SNY) are exploring the use of Dupixent in other indications such as asthma, pediatric AD, nasal polyps, and eosinophilic esophagitis.
London-based pharma giant, AstraZeneca plc (AZN) has a strong product portfolio and is one of the key players in the global cardiovascular market.